Transcriptomics

Dataset Information

0

Development of MDM2-targeting PROTAC technology for advancing bone regeneration


ABSTRACT: MDM2 inhibitor remarkably induced biomineralization in hDPSCs but it remained the problem that p53 activation is insufficient due to MDM2-p53 autoregulatory feedback loop. To overcome the limitation of the MDM2 inhibitors, we applied proteolysis targeting chimera (PROTAC), a technology that degrades a protein of interest (POI) by intracellular ubiquitin-proteasome system. Hence, we propose a strategy to induce hard tissue regeneration by MDM2-targeting PROTAC technology. We selected Nutlin-3 of POI ligand among various MDM2 inhibitors based on the screening process, and the selected CRBN of E3 ligase ligand. The MDM2-PROTAC synthesis platform was designed by each ligand combination. By performing the degradation test for selected compounds, we evaluated the characteristics of the developed MDM2 PROTAC such as the maximal degradation concentration (DCmax), the half of maximal degradation concentration (DC50), and half-lifetime. To investigate gene expression profiling of MDM2-targeting small molecules, we conducted RNA-sequencing under MDM2 PROTAC and Nutlin-3 (POI ligand) treated conditions. We not only confirmed a robust effect on biomineralization by MDM2-targeting small molecules but also demonstrated the potent osteogenic differentiation ability of MDM2 PROTAC when compared to an MDM2 inhibitor. MDM2-PROTAC significantly increased mRNA levels of osteogenic differentiation marker genes. Also, the significant bone generation effect of MDM2 PROTAC was validated in an ovariectomy (OVX)-induced osteoporosis animal model. Through these results, it is expected that a new therapeutic modality for hard tissue regeneration will be possible, and the application range of the PROTAC system can be expanded.

ORGANISM(S): Homo sapiens

PROVIDER: GSE255297 | GEO | 2024/06/11

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-07-30 | PXD009290 | Pride
2016-05-02 | GSE80716 | GEO
2024-05-17 | GSE243615 | GEO
2013-10-23 | E-GEOD-46992 | biostudies-arrayexpress
2023-12-06 | PXD045052 | Pride
2024-05-17 | GSE262938 | GEO
2014-12-25 | E-GEOD-59841 | biostudies-arrayexpress
2014-12-25 | GSE59841 | GEO
2022-09-22 | PXD036865 | Pride
2013-10-23 | GSE46992 | GEO